Allergy Therapeutics (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announced that the first subject has been dosed in the pivotal Phase III G306 trial, to..
Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has today announced the appointments of Anthony Parker and Zheqing (Simon) Shen as Non-Executive Directors of..
Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announced the appointment of Martin Hopcroft to the role of Interim Chief Financial Officer (CFO)...
Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergen immunotherapy, has announced that it will resume production at the Freeman facility, part of its Worthing, UK..
– Phase I VLP Peanut PROTECT trial, incorporating ground-breaking VLP technology, commencing shortly – Highly successful exploratory field trial for Grass MATA MPL, achieved 40% improvement in combined symptom and medication score..
Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has today announced that company management will participate in a fireside chat at the upcoming H.C...
– Phase I VLP Peanut PROTECT trial incorporating ground-breaking VLP technology proceeding as planned with site initiation visits imminent – Pivotal Phase III Grass MATA MPL trial on track to start..
Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical company specialising in allergy immunotherapy, has announced that the Group will be sharing key scientific findings from across its research portfolio at..
Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has announced that company management will present at the H.C. Wainwright Global Investment Conference being held..
Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, stated today that will share positive new data from across its research portfolio at the joint..
Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, today announced that Manuel Llobet, Chief Executive Officer, Nick Wykeman, Chief Financial Officer, and Alan Bullimore,..
Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announced its unaudited interim results for the six months ended 31 December 2021. · Portfolio focused..
Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has announced the presentation of positive new data from its two lead immunotherapy programmes at the..
Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announced that the United States Food & Drug Administration (FDA) has cleared the Group’s Investigational..
Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, has provided a trading update for the six months ended 31 December 2021 ahead of its..
Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, announced today that Peter Jensen, Non-Executive Chairman, has purchased 30,000 ordinary shares of 0.1 pence each..
Shares of Allergy Therapeutics with EPIC code: LON:AGY has risen 3.55% or 1.25 points during the course of today’s session so far. Investors have stayed positive while the stock has..
Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, has announced the appointment of Cheryl MacDiarmid as a Non-Executive Director of the Company, with effect..
Allergy Therapeutics announces positive top line results from G309 exploratory field trial to evaluate efficacy and safety of Grass MATA MPL – Primary endpoint Combined Symptom Medication Score (CSMS) achieved with..
Allergy Therapeutics plc (LON:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, today announced its preliminary results for the year ended 30th June 2021. Financial highlights · 8% revenue..
